title: Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer.
abstract: OBJECTIVE
  Based on in vitro evidence of radiosensitization by Betaseron (beta-IFN), a Phase I/II study was undertaken to determine toxicity and response using combined radiation (RT) and B-IFN in patients with unresectable Stage III and nonsmall cell lung cancer.
  
  
  METHODS
  Varying doses of beta-IFN(10 to 90 x 10(6) IU) were administered IV immediately preceding RT on the first three days of weeks 1, 3, and 5. The RT dose was 1.8 Gy/day, 5 days/week for a total of 54 or 59.4 Gy.
  
  
  RESULTS
  Thirty-nine patients were entered, 32 of whom were evaluable. The median follow-up time at time of analysis was 60 months. Responses were based on CT scan. The response rate for the total group was 81% with 44% achieving complete response. Seventy-eight percent of patients with complete response survived a minimum of 21 months. Twenty-six patients had Stage III A/B disease with a median tumor size of 6.5 cm. and median survival was 19.7 months. The 5-year actuarial survival for this group was 31%, with a plateau persisting after 3 years. There were no treatment related deaths nor any event of life threatening toxicity. Of eight patients surviving 3-5 years, no long-term toxicity has been observed. Karnofsky indices were 90-100 and respiratory symptoms were minimal.
  
  
  CONCLUSIONS
  beta-IFN is well-tolerated. Response and survival rates are sufficiently encouraging to warrant further investigation in a randomized trial which has been accepted as an RTOG study awaiting drug availability.
authors.affiliation: University of Rochester Cancer Center, NY.
authors.forename: S
authors.initials: S
authors.lastname: McDonald
authors.forename: A Y
authors.initials: AY
authors.lastname: Chang
authors.forename: P
authors.initials: P
authors.lastname: Rubin
authors.forename: J
authors.initials: J
authors.lastname: Wallenberg
authors.forename: I S
authors.initials: IS
authors.lastname: Kim
authors.forename: S
authors.initials: S
authors.lastname: Sobel
authors.forename: J
authors.initials: J
authors.lastname: Smith
authors.forename: P
authors.initials: P
authors.lastname: Keng
authors.forename: A
authors.initials: A
authors.lastname: Muhs
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000503:physiopathology / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use*; D008168:Lung / Q000503:physiopathology; D008175:Lung Neoplasms / Q000401:mortality / Q000503:physiopathology / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D015996:Survival Rate
chemical_list: D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a